查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128107

分散式臨床試驗市場規模、佔有率、成長及全球產業分析、區域趨勢及預測（2026年至2034年）

Decentralized Clinical Trials Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 261 Pages | 商品交期: 2-3個工作天內

價格

分散式臨床試驗市場的成長要素

全球分散式臨床試驗市場預計在2025年達到95.6億美元，2026年成長至109.2億美元，並在2034年達到293.7億美元，預測期內複合年成長率（CAGR）為13.2%。北美地區將在2025年佔最大的市場佔有率，達到42.46%，這主要得益於數位醫療技術的應用、先進的臨床研究基礎設施以及對遠距臨床試驗解決方案投資的不斷成長。

分散式臨床試驗 (DCT) 利用數位平台、遠端醫療裝置、遠端患者監護、電子知情同意 (eConsent) 和電子病患報告結局 (ePRO) 等技術，使部分或全部臨床試驗活動能夠在傳統研究機構之外進行。慢性病盛行率的不斷上升、癌症和罕見疾病研究的拓展、以患者為中心的研究模式的興起以及人工智慧 (AI) 的日益普及，正在加速分佈式臨床試驗在全球範圍內的推廣應用。

市場趨勢

隨著人工智慧 (AI) 的不斷融合，分散式臨床試驗正在發生變革，患者招募、試驗匹配、遠端監測、預測性入組和參與者保留率均顯著提升。 AI 驅動的分析技術使臨床試驗贊助者能夠分析電子健康記錄、基因組資料庫和真實世界數據 (REW)，從而更有效率地識別合格的參與者。遠端醫療、穿戴式健康設備、遠距監測平台和數位資料收集工具也逐漸成為分散式臨床試驗的標準組成部分，在減輕患者負擔的同時，提高了研究效率。根據塔夫茨大學醫學院預測，到 2025 年，AI 驅動的臨床試驗活動將縮短約 18% 的時間，凸顯了智慧數位解決方案在臨床研究中日益成長的重要性。

市場促進因素

與慢性病、腫瘤和罕見疾病相關的臨床研究數量不斷增加，是推動市場擴張的主要動力之一。這些研究通常需要持續的病患監測、更廣泛的地域參與以及長期的隨訪，因此分散式臨床試驗模式非常有效。根據美國國家生物技術資訊中心 (NCBI) 預測，到 2026 年，全球將有約 586,665 項臨床試驗啟動，顯示對高效試驗管理解決方案的需求日益成長。醫療保健支出不斷增加、製藥公司研發管線不斷擴展、個人化醫療的推進以及大型合約研究組織 (CRO) 投資的增加，都進一步促進了市場成長。

市場限制因素

儘管成長前景強勁，但高昂的實施成本仍然是一項重大挑戰。建構分散式臨床試驗的基礎設施需要在數位平台、網路安全、遠端醫療系統、物流、電子知情同意解決方案和遠端監測技術方面進行大量投資。此外，各機構還需要在人才培育、IT整合、法規遵循和供應商管理方面進行投入。根據賽默飛世爾科技公司的一項調查，52.7%的受訪者表示，他們在分散式臨床試驗中使用了來自多家供應商的技術，這增加了營運複雜性和實施成本。

市場機遇

由於醫療基礎設施的不斷完善和臨床研究活動的日益活躍，新興經濟體正迎來巨大的成長機會。中國、巴西、印度和墨西哥等國家正吸引越來越多的製藥公司投資，這些公司尋求的是多元化的患者群體和經濟高效的研究環境。根據美國商務部國際貿易局預測，巴西的醫療保健支出預計將在2025年達到約1,350億美元，這將為分散式臨床試驗的發展創造有利條件。數位醫療基礎設施的改善以及人們對以患者為中心的研究模式日益成長的認知，預計將進一步加速市場擴張。

市場挑戰

一些開發中國家科研基礎設施的匱乏持續阻礙市場滲透。許多新興地區面臨許多挑戰，例如訓練有素的臨床研究專業人員短缺、法規結構不統一、物流網路不完善以及數位醫療普及率低等。世界衛生組織（世衛組織）預測，到2025年，巴西僅將進行22,832項臨床試驗，凸顯了已開發國家和新興國家醫療衛生研究生態系統之間的巨大差距。

細分分析

以類型來看，市場可分為解決方案和服務兩大類。預計到2025年，由於受試者招募、遠端醫療協調、電子知情同意、遠端監測和分散式試驗管理等方面的需求不斷成長，服務類市場將佔主導地位。同時，解決方案類市場預計在預測期內將實現13.3%的複合年成長率。

從設計角度來看，市場可分為「完全分散式臨床試驗」和「混合分散式臨床試驗」。到2025年，「混合分散式臨床試驗」（結合傳統現場訪視和虛擬醫療技術，提供更大的柔軟性）將佔最大市場佔有率。 「完全分散式臨床試驗」市場預計到2034年將以13.5%的複合年成長率成長。

隨著大規模臨床研究的增加，試驗階段的III期臨床試驗預計將推動市場發展，到2025年將佔46.7%的市場。 IV期臨床試驗預計在預測期內將維持穩定成長。

按治療領域分類，腫瘤學在2025年仍將是領先領域，預計到2026年將佔市場佔有率的31.4%，這主要得益於癌症發病率的上升和分散式腫瘤臨床試驗的日益普及。循環系統醫學預計也將顯著成長。

按終端用戶分類，製藥和生物技術公司將在2025年佔最大市場佔有率，預計到2026年將佔50.3%的市場佔有率，這反映出對分散式臨床研究的投資不斷增加。醫療設備製造商預計將在預測期內實現最快成長。

區域展望

北美仍然是最大的區域市場，預計到 2025 年將達到 40.6 億美元。同時，在製藥業強大的研發投入和先進的數位醫療基礎設施的支持下，美國市場預計到 2026 年將達到 42.2 億美元。

預計到 2026 年，歐洲市場規模將達到 29.7 億美元，年複合成長率達 12.6%，主要得益於介入性臨床試驗的擴展和分散式研究技術的日益普及。

預計到2026年，亞太地區市場規模將達到22.5億美元，主要得益於中國、日本和印度醫療保健投資的增加以及臨床試驗活動的擴展。其中，中國預計將達到9.7億美元，日本和印度預計將分別達到4.3億美元和2.2億美元。

預計到 2026 年，拉丁美洲市場規模將達到 5.9 億美元，而中東和非洲地區預計將繼續保持溫和成長，海灣合作理事會市場規模估計為 2.5 億美元。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 臨床試驗數量，主要國家/地區，2025 年
  • 研發支出概覽，主要公司
  • 產業重大發展：合併、收購與合作。

第5章：全球分散式臨床試驗市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按類型
    • 解決方案
    • 服務
  • 市場分析、洞察與預測：精心設計。
    • 完全分散的臨床試驗
    • 混合分散式臨床試驗
  • 市場分析、洞察與預測：按階段分類
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 市場分析、洞察與預測：按治療領域分類
    • 腫瘤學
    • 感染疾病
    • 神經病學
    • 循環系統
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 製藥和生物技術公司
    • 醫療設備製造商
    • CRO
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美分散式臨床試驗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲分散式臨床試驗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區分散式臨床試驗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 澳洲
    • 中國
    • 印度
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲分散式臨床試驗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東與非洲分散式臨床試驗市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • IQVIA
    • ICON plc
    • Thermo Fisher Scientific Inc.
    • Parexel International（MA）Corporation
    • Medpace
    • Lacorp
    • Oracle
    • Signant Health
    • Fortrea
    • Tecex Medical
Product Code: FBI117303

Growth Factors of decentralized clinical trials Market

The global decentralized clinical trials market was valued at USD 9.56 billion in 2025 and is projected to grow from USD 10.92 billion in 2026 to USD 29.37 billion by 2034, registering a CAGR of 13.2% during the forecast period. North America accounted for the largest market share of 42.46% in 2025, supported by widespread adoption of digital healthcare technologies, advanced clinical research infrastructure, and increasing investment in remote trial solutions.

Decentralized clinical trials (DCTs) allow some or all clinical trial activities to take place outside traditional research sites through digital platforms, telemedicine, wearable devices, remote patient monitoring, electronic consent (eConsent), and electronic patient-reported outcomes (ePRO). The growing prevalence of chronic diseases, increasing oncology and rare disease studies, rising patient-centric research models, and expanding use of artificial intelligence are accelerating the adoption of decentralized clinical trials worldwide.

Market Trends

The growing integration of artificial intelligence (AI) is transforming decentralized clinical trials by improving patient recruitment, trial matching, remote monitoring, predictive enrollment, and participant retention. AI-powered analytics enable sponsors to analyze electronic health records, genomic databases, and real-world evidence to identify eligible participants more efficiently. Telemedicine, wearable health devices, remote monitoring platforms, and digital data collection tools are also becoming standard components of decentralized trials, helping reduce patient burden while improving study efficiency. According to Tufts University School of Medicine, AI-assisted clinical trial activities delivered approximately 18% time savings in 2025, highlighting the increasing importance of intelligent digital solutions in clinical research.

Market Drivers

The increasing number of chronic disease, oncology, and rare disease clinical studies is one of the primary drivers supporting market expansion. These studies often require continuous patient monitoring, broader geographic participation, and long-term follow-up, making decentralized clinical trial models highly effective. According to the National Center for Biotechnology Information (NCBI), approximately 586,665 clinical trial studies were registered globally in 2026, reflecting the growing need for efficient trial management solutions. Rising healthcare expenditure, expansion of pharmaceutical research pipelines, personalized medicine initiatives, and increasing investments by major contract research organizations are further supporting market growth.

Market Restraints

Despite strong growth prospects, high implementation costs remain a significant challenge. Establishing decentralized clinical trial infrastructure requires substantial investment in digital platforms, cybersecurity, telehealth systems, logistics, electronic consent solutions, and remote monitoring technologies. Organizations must also invest in workforce training, IT integration, regulatory compliance, and vendor management. According to Thermo Fisher Scientific, 52.7% of respondents reported using technologies from multiple vendors in decentralized clinical trials, increasing operational complexity and implementation costs.

Market Opportunities

Emerging economies present substantial growth opportunities due to expanding healthcare infrastructure and increasing clinical research activities. Countries such as China, Brazil, India, and Mexico are attracting greater investments from pharmaceutical companies seeking diverse patient populations and cost-effective research environments. According to the International Trade Administration, Brazil's healthcare expenditure reached approximately USD 135.0 billion in 2025, creating favorable conditions for decentralized clinical trial adoption. Improved digital healthcare infrastructure and growing awareness of patient-centric research models are expected to further accelerate market expansion.

Market Challenges

Limited research infrastructure in several developing countries continues to restrict market penetration. Many emerging regions face shortages of trained clinical research professionals, inconsistent regulatory frameworks, inadequate logistics networks, and limited digital healthcare adoption. According to the World Health Organization, Brazil conducted only 22,832 clinical trials in 2025, highlighting the gap between developed and emerging healthcare research ecosystems.

Segmentation Analysis

Based on type, the market is segmented into solutions and services. The services segment dominated the market in 2025 due to increasing demand for patient recruitment, telehealth coordination, eConsent implementation, remote monitoring, and decentralized trial management. Meanwhile, the solutions segment is projected to register a CAGR of 13.3% during the forecast period.

By design, the market is categorized into fully decentralized trials and hybrid decentralized trials. Hybrid decentralized trials accounted for the largest share in 2025 because they combine traditional site visits with virtual healthcare technologies, offering greater flexibility. The fully decentralized trials segment is expected to grow at a CAGR of 13.5% through 2034.

Based on phase, Phase III clinical trials dominated the market with a 46.7% share in 2025, supported by increasing large-scale clinical studies. The Phase IV segment is anticipated to witness steady expansion during the forecast period.

By therapeutic area, oncology remained the leading segment in 2025 and is expected to account for 31.4% of the market in 2026, driven by the increasing incidence of cancer and rising adoption of decentralized oncology trials. Cardiology is also projected to experience significant growth.

Based on end user, pharmaceutical and biotechnological companies held the dominant share in 2025 and are expected to account for 50.3% of the market in 2026, reflecting increasing investments in decentralized clinical research. Medical device companies are expected to record the fastest growth during the forecast period.

Regional Outlook

North America remained the largest regional market, reaching USD 4.06 billion in 2025, while the U.S. market is estimated at USD 4.22 billion in 2026, supported by strong pharmaceutical R&D spending and advanced digital healthcare infrastructure.

Europe is projected to reach USD 2.97 billion in 2026, growing at a CAGR of 12.6%, driven by expanding interventional clinical studies and rising adoption of decentralized research technologies.

Asia Pacific is expected to achieve USD 2.25 billion in 2026, supported by increasing healthcare investments and growing clinical trial activity across China, Japan, and India. China alone is projected to generate USD 0.97 billion, while Japan and India are expected to reach USD 0.43 billion and USD 0.22 billion, respectively.

Latin America is projected to reach USD 0.59 billion in 2026, while the Middle East & Africa continues to witness gradual expansion, with the GCC market estimated at USD 0.25 billion.

Competitive Landscape

The decentralized clinical trials market remains highly competitive, with major companies focusing on technology expansion, AI integration, acquisitions, and strategic collaborations. Leading participants include IQVIA, ICON plc, Thermo Fisher Scientific Inc., Parexel International, Medpace, Labcorp, Oracle, Signant Health, Fortrea, and Tecex Medical. Recent developments include Labcorp's collaboration with Hawthorne Effect to enhance decentralized trial capabilities, Signant Health's partnership with IQVIA for expanding eClinical solutions, and Cenmed's collaboration with Curavit Clinical Research to strengthen decentralized clinical trial logistics.

Conclusion

The decentralized clinical trials market is poised for strong expansion as pharmaceutical companies increasingly adopt digital, patient-centric research models. Growing use of artificial intelligence, telemedicine, wearable technologies, and remote monitoring is transforming clinical trial operations by improving patient recruitment, engagement, and study efficiency. Although high implementation costs and infrastructure limitations remain challenges, rising healthcare investments, expanding clinical research in emerging economies, and continuous technological innovation are expected to drive sustained market growth. With the market projected to increase from USD 9.56 billion in 2025 to USD 29.37 billion by 2034, decentralized clinical trials are expected to become an integral component of the future clinical research ecosystem.

Segmentation By Type, Design, Phase, Therapeutic Area, End User, and Region

By Type * Solutions

  • Services

By Design * Fully Decentralized Trials

  • Hybrid Decentralized Trials

By Phase * Phase I

  • Phase II
  • Phase III
  • Phase IV

By Therapeutic Area * Oncology

  • Infectious Diseases
  • Neurology
  • Cardiology
  • Others

By End User * Pharmaceutical & Biotechnological Companies

  • Medical Device Companies
  • CROs
  • Others

By Region * North America (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country)

    • U.S. (By Design)
    • Canada (By Design)
  • Europe (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
    • U.K. (By Design)
    • Germany (By Design)
    • France (By Design)
    • Italy (By Design)
    • Spain (By Design)
    • Scandinavia (By Design)
    • Rest of Europe (By Design)
  • Asia Pacific (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
    • China (By Design)
    • Japan (By Design)
    • India (By Design)
    • Australia (By Design)
    • Southeast Asia (By Design)
    • Rest of Asia Pacific (By Design)
  • Latin America (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
    • Brazil (By Design)
    • Mexico (By Design)
    • Rest of Latin America (By Design)
  • Middle East & Africa (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
    • GCC (By Design)
    • South Africa (By Design)
    • Rest of the Middle East & Africa (By Design)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Number of Clinical Trials, Key Countries/Regions, 2025
  • 4.2. Overview of R&D Expenditures, Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Solutions
    • 5.1.2. Services
  • 5.2. Market Analysis, Insights and Forecast - By Design
    • 5.2.1. Fully Decentralized Trials
    • 5.2.2. Hybrid Decentralized Trials
  • 5.3. Market Analysis, Insights and Forecast - By Phase
    • 5.3.1. Phase I
    • 5.3.2. Phase II
    • 5.3.3. Phase III
    • 5.3.4. Phase IV
  • 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 5.4.1. Oncology
    • 5.4.2. Infectious Diseases
    • 5.4.3. Neurology
    • 5.4.4. Cardiology
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Pharmaceutical & Biotechnological Companies
    • 5.5.2. Medical Device Companies
    • 5.5.3. CROs
    • 5.5.4. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Solutions
    • 6.1.2. Services
  • 6.2. Market Analysis, Insights and Forecast - By Design
    • 6.2.1. Fully Decentralized Trials
    • 6.2.2. Hybrid Decentralized Trials
  • 6.3. Market Analysis, Insights and Forecast - By Phase
    • 6.3.1. Phase I
    • 6.3.2. Phase II
    • 6.3.3. Phase III
    • 6.3.4. Phase IV
  • 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 6.4.1. Oncology
    • 6.4.2. Infectious Diseases
    • 6.4.3. Neurology
    • 6.4.4. Cardiology
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Pharmaceutical & Biotechnological Companies
    • 6.5.2. Medical Device Companies
    • 6.5.3. CROs
    • 6.5.4. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
      • 6.6.1.1. By Design
    • 6.6.2. Canada
      • 6.6.2.1. By Design

7. Europe Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Solutions
    • 7.1.2. Services
  • 7.2. Market Analysis, Insights and Forecast - By Design
    • 7.2.1. Fully Decentralized Trials
    • 7.2.2. Hybrid Decentralized Trials
  • 7.3. Market Analysis, Insights and Forecast - By Phase
    • 7.3.1. Phase I
    • 7.3.2. Phase II
    • 7.3.3. Phase III
    • 7.3.4. Phase IV
  • 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 7.4.1. Oncology
    • 7.4.2. Infectious Diseases
    • 7.4.3. Neurology
    • 7.4.4. Cardiology
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Pharmaceutical & Biotechnological Companies
    • 7.5.2. Medical Device Companies
    • 7.5.3. CROs
    • 7.5.4. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
      • 7.6.1.1. By Design
    • 7.6.2. Germany
      • 7.6.2.1. By Design
    • 7.6.3. France
      • 7.6.3.1. By Design
    • 7.6.4. Spain
      • 7.6.4.1. By Design
    • 7.6.5. Italy
      • 7.6.5.1. By Design
    • 7.6.6. Scandinavia
      • 7.6.6.1. By Design
    • 7.6.7. Rest of Europe
      • 7.6.7.1. By Design

8. Asia Pacific Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Solutions
    • 8.1.2. Services
  • 8.2. Market Analysis, Insights and Forecast - By Design
    • 8.2.1. Fully Decentralized Trials
    • 8.2.2. Hybrid Decentralized Trials
  • 8.3. Market Analysis, Insights and Forecast - By Phase
    • 8.3.1. Phase I
    • 8.3.2. Phase II
    • 8.3.3. Phase III
    • 8.3.4. Phase IV
  • 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 8.4.1. Oncology
    • 8.4.2. Infectious Diseases
    • 8.4.3. Neurology
    • 8.4.4. Cardiology
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Pharmaceutical & Biotechnological Companies
    • 8.5.2. Medical Device Companies
    • 8.5.3. CROs
    • 8.5.4. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
      • 8.6.1.1. By Design
    • 8.6.2. Australia
      • 8.6.2.1. By Design
    • 8.6.3. China
      • 8.6.3.1. By Design
    • 8.6.4. India
      • 8.6.4.1. By Design
    • 8.6.5. Southeast Asia
      • 8.6.5.1. By Design
    • 8.6.6. Rest of Asia Pacific
      • 8.6.6.1. By Design

9. Latin America Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Solutions
    • 9.1.2. Services
  • 9.2. Market Analysis, Insights and Forecast - By Design
    • 9.2.1. Fully Decentralized Trials
    • 9.2.2. Hybrid Decentralized Trials
  • 9.3. Market Analysis, Insights and Forecast - By Phase
    • 9.3.1. Phase I
    • 9.3.2. Phase II
    • 9.3.3. Phase III
    • 9.3.4. Phase IV
  • 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 9.4.1. Oncology
    • 9.4.2. Infectious Diseases
    • 9.4.3. Neurology
    • 9.4.4. Cardiology
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Pharmaceutical & Biotechnological Companies
    • 9.5.2. Medical Device Companies
    • 9.5.3. CROs
    • 9.5.4. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
      • 9.6.1.1. By Design
    • 9.6.2. Mexico
      • 9.6.2.1. By Design
    • 9.6.3. Rest of Latin America
      • 9.6.3.1. By Design

10. Middle East & Africa Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Solutions
    • 10.1.2. Services
  • 10.2. Market Analysis, Insights and Forecast - By Design
    • 10.2.1. Fully Decentralized Trials
    • 10.2.2. Hybrid Decentralized Trials
  • 10.3. Market Analysis, Insights and Forecast - By Phase
    • 10.3.1. Phase I
    • 10.3.2. Phase II
    • 10.3.3. Phase III
    • 10.3.4. Phase IV
  • 10.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 10.4.1. Oncology
    • 10.4.2. Infectious Diseases
    • 10.4.3. Neurology
    • 10.4.4. Cardiology
    • 10.4.5. Others
  • 10.5. Market Analysis, Insights and Forecast - By End User
    • 10.5.1. Pharmaceutical & Biotechnological Companies
    • 10.5.2. Medical Device Companies
    • 10.5.3. CROs
    • 10.5.4. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
      • 10.6.1.1. By Design
    • 10.6.2. South Africa
      • 10.6.2.1. By Design
    • 10.6.3. Rest of the Middle East & Africa
      • 10.6.3.1. By Design

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. IQVIA
    • 11.2.2. ICON plc
    • 11.2.3. Thermo Fisher Scientific Inc.
    • 11.2.4. Parexel International (MA) Corporation
    • 11.2.5. Medpace
    • 11.2.6. Lacorp
    • 11.2.7. Oracle
    • 11.2.8. Signant Health
    • 11.2.9. Fortrea
    • 11.2.10. Tecex Medical

List of Tables

  • Table 1: Global Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 2: Global Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 3: Global Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Phase, 2021-2034
  • Table 4: Global Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 5: Global Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 6: Global Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 7: North America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 8: North America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 9: North America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Phase, 2021-2034
  • Table 10: North America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 11: North America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 12: North America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 14: Canada Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 15: Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 17: Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Phase, 2021-2034
  • Table 18: Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 19: Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 20: Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Germany Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 22: U.K. Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 23: France Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 24: Italy Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 25: Spain Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 26: Scandinavia Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 27: Rest of Europe Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 28: Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 29: Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 30: Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Phase, 2021-2034
  • Table 31: Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 32: Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 33: Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 34: China Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 35: Japan Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 36: India Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 37: Australia Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 38: Southeast Asia Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 39: Rest of Asia Pacific Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 40: Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 41: Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 42: Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Phase, 2021-2034
  • Table 43: Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 44: Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 45: Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Brazil Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 47: Mexico Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 48: Rest of Latin America Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 49: Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 50: Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 51: Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Phase, 2021-2034
  • Table 52: Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 53: Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 54: Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 55: GCC Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 56: South Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034
  • Table 57: Rest of the Middle East & Africa Decentralized Clinical Trials Market Revenue (USD Billion) Forecast, by Design, 2021-2034

List of Figures

  • Figure 1: Global Decentralized Clinical Trials Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Decentralized Clinical Trials Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Decentralized Clinical Trials Market Value Share (%), by Design, 2025 & 2034
  • Figure 4: Global Decentralized Clinical Trials Market Value Share (%), by Phase, 2025 & 2034
  • Figure 5: Global Decentralized Clinical Trials Market Value Share (%), by Therapeutic Area, 2025 & 2034
  • Figure 6: Global Decentralized Clinical Trials Market Value Share (%), by End User, 2025 & 2034
  • Figure 7: Global Decentralized Clinical Trials Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Decentralized Clinical Trials Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 9: North America Decentralized Clinical Trials Market Value Share (%), by Type, 2025
  • Figure 10: North America Decentralized Clinical Trials Market Value (USD Billion), by Design, 2025 & 2034
  • Figure 11: North America Decentralized Clinical Trials Market Value Share (%), by Design, 2025
  • Figure 12: North America Decentralized Clinical Trials Market Value (USD Billion), by Phase, 2025 & 2034
  • Figure 13: North America Decentralized Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 14: North America Decentralized Clinical Trials Market Value (USD Billion), by Therapeutic Area, 2025 & 2034
  • Figure 15: North America Decentralized Clinical Trials Market Value Share (%), by Therapeutic Area, 2025
  • Figure 16: North America Decentralized Clinical Trials Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 17: North America Decentralized Clinical Trials Market Value Share (%), by End User, 2025
  • Figure 18: North America Decentralized Clinical Trials Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 19: North America Decentralized Clinical Trials Market Value Share (%), By Country, 2025
  • Figure 20: Europe Decentralized Clinical Trials Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 21: Europe Decentralized Clinical Trials Market Value Share (%), by Type, 2025
  • Figure 22: Europe Decentralized Clinical Trials Market Value (USD Billion), by Design, 2025 & 2034
  • Figure 23: Europe Decentralized Clinical Trials Market Value Share (%), by Design, 2025
  • Figure 24: Europe Decentralized Clinical Trials Market Value (USD Billion), by Phase, 2025 & 2034
  • Figure 25: Europe Decentralized Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 26: Europe Decentralized Clinical Trials Market Value (USD Billion), by Therapeutic Area, 2025 & 2034
  • Figure 27: Europe Decentralized Clinical Trials Market Value Share (%), by Therapeutic Area, 2025
  • Figure 28: Europe Decentralized Clinical Trials Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 29: Europe Decentralized Clinical Trials Market Value Share (%), by End User, 2025
  • Figure 30: Europe Decentralized Clinical Trials Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Decentralized Clinical Trials Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Decentralized Clinical Trials Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 33: Asia Pacific Decentralized Clinical Trials Market Value Share (%), by Type, 2025
  • Figure 34: Asia Pacific Decentralized Clinical Trials Market Value (USD Billion), by Design, 2025 & 2034
  • Figure 35: Asia Pacific Decentralized Clinical Trials Market Value Share (%), by Design, 2025
  • Figure 36: Asia Pacific Decentralized Clinical Trials Market Value (USD Billion), by Phase, 2025 & 2034
  • Figure 37: Asia Pacific Decentralized Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 38: Asia Pacific Decentralized Clinical Trials Market Value (USD Billion), by Therapeutic Area, 2025 & 2034
  • Figure 39: Asia Pacific Decentralized Clinical Trials Market Value Share (%), by Therapeutic Area, 2025
  • Figure 40: Asia Pacific Decentralized Clinical Trials Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 41: Asia Pacific Decentralized Clinical Trials Market Value Share (%), by End User, 2025
  • Figure 42: Asia Pacific Decentralized Clinical Trials Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Decentralized Clinical Trials Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Decentralized Clinical Trials Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 45: Latin America Decentralized Clinical Trials Market Value Share (%), by Type, 2025
  • Figure 46: Latin America Decentralized Clinical Trials Market Value (USD Billion), by Design, 2025 & 2034
  • Figure 47: Latin America Decentralized Clinical Trials Market Value Share (%), by Design, 2025
  • Figure 48: Latin America Decentralized Clinical Trials Market Value (USD Billion), by Phase, 2025 & 2034
  • Figure 49: Latin America Decentralized Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 50: Latin America Decentralized Clinical Trials Market Value (USD Billion), by Therapeutic Area, 2025 & 2034
  • Figure 51: Latin America Decentralized Clinical Trials Market Value Share (%), by Therapeutic Area, 2025
  • Figure 52: Latin America Decentralized Clinical Trials Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 53: Latin America Decentralized Clinical Trials Market Value Share (%), by End User, 2025
  • Figure 54: Latin America Decentralized Clinical Trials Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Decentralized Clinical Trials Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Decentralized Clinical Trials Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 57: Middle East & Africa Decentralized Clinical Trials Market Value Share (%), by Type, 2025
  • Figure 58: Middle East & Africa Decentralized Clinical Trials Market Value (USD Billion), by Design, 2025 & 2034
  • Figure 59: Middle East & Africa Decentralized Clinical Trials Market Value Share (%), by Design, 2025
  • Figure 60: Middle East & Africa Decentralized Clinical Trials Market Value (USD Billion), by Phase, 2025 & 2034
  • Figure 61: Middle East & Africa Decentralized Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 62: Middle East & Africa Decentralized Clinical Trials Market Value (USD Billion), by Therapeutic Area, 2025 & 2034
  • Figure 63: Middle East & Africa Decentralized Clinical Trials Market Value Share (%), by Therapeutic Area, 2025
  • Figure 64: Middle East & Africa Decentralized Clinical Trials Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 65: Middle East & Africa Decentralized Clinical Trials Market Value Share (%), by End User, 2025
  • Figure 66: Middle East & Africa Decentralized Clinical Trials Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Decentralized Clinical Trials Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Decentralized Clinical Trials Market Share (%), By Company, 2025